Breviscapine effects on the expression of proliferating cell nuclear antigen and c-fos in the testis of diabetic rat models

doi:10.3969/j.issn.2095-4344.2015.18.023

Abstract

Abstract:

BACKGROUND: Breviscapine has been shown to impact the reproductive capacity in rats with type 2 diabetes mellitus, but few reports concerned its mechanism of action.
OBJECTIVE: To study the effects of breviscapine on proliferating cell nuclear antigen and proto-oncogene c-fos expression in testis of type 2 diabetes mellitus rats.
METHODS: Totally 36 healthy male rats were randomly divided into control group, model group and breviscapine group with 12 rats in each group. In the model group and breviscapine group, rat models of type 2 diabetes mellitus were established by continuous intraperitoneal injection of streptozotocin. Blood glucose reaching16.7 mmol/L in rats was considered as the standard of model induction. In the control group, rats were given an equal volume of citrate buffer solution by single intraperitoneal injection. In the breviscapine group, rats were administered breviscapine 10 mg/(kg•d) for 4 consecutive weeks by intraperitoneal injection. Rats in the other two groups were injected with an equal volume of physiological saline at the same time point.
RESULTS AND CONCLUSION: After 4 weeks of intervention, serum testosterone testing, immunohistochemistry and PCR results showed that serum testosterone levels, proliferating cell nuclear antigen, c-Fos protein and mRNA expression: control group > breviscapine group > model group (P < 0.05); blood glucose concentration: the control group < breviscapine group < model group (P < 0.05). Results confirmed that breviscapine can protect the reproductive function in type 2 diabetes mellitus rats by enhancing the expression of proliferating cell nuclear
antigen and c-fos.

中国组织工程研究杂志出版内容重点：肾移植；肝移植；移植；心脏移植；组织移植；皮肤移植；皮瓣移植；血管移植；器官移植；组织工程

全文链接：

Key words: Tissue Engineering, Diabetes Mellitus, Proto-Oncogenes, Testosterone

CLC Number:

R318

Long Ling-li, Zheng Shu-hui, Li Yu-bin. Breviscapine effects on the expression of proliferating cell nuclear antigen and c-fos in the testis of diabetic rat models[J]. Chinese Journal of Tissue Engineering Research, 2015, 19(18): 2917-2922.

Figures/Tables 4

References

[1] 王秀虹,余薇.茶多酚对糖尿病大鼠睾丸损伤的保护作用[J].时珍国医国药,2013,24(9):2138-2139.
[2] 万强,罗辉.山楂叶总黄酮对糖尿病大鼠睾丸损伤的保护作用[J].现代中西医结合杂志,2013,22(35):3889-3891.
[3] 刘英姿,刘浩然,周源,等.山茱萸总皂苷对糖尿病大鼠睾丸病变的改善作用[J].中国现代医学杂志,2012,22(22):10-13.
[4] 赵连志,杨松鹤,李山山,等.丝胶预处理对糖尿病大鼠睾丸生长激素和生长激素受体表达的作用[J].中国老年学杂志,2012,32(9): 1850-1852.
[5] 马丁,兰晓煦,陈明明,等.营养性肥胖对青春期大鼠睾丸生殖细胞中FAS/FAS-L凋亡途径的影响[J].中国男科学杂志,2011,25(9): 33-36,39.
[6] 史杰,宫燕,谢高宇,等.淫羊藿总黄酮对四氧嘧啶诱导糖尿病小鼠睾丸病变的保护作用[J].中国应用生理学杂志,2013,29(5): 428-431.
[7] 马倩倩,李锦平,武莉,等.灯盏花素对2型糖尿病大鼠糖脂代谢的影响[J].中国实验方剂学杂志,2014,20(13):176-179.
[8] Nagai N, Murao T, Ito Y. Enhancing effects of sericin on corneal wound healing in Otsuka Long-Evans Tokushima fatty rats as a model of human type 2 diabetes. Biol Pharm Bull. 2009;32(9):1594-1599.
[9] 宋成军,付文亮,陈志宏.丝胶预处理对2型糖尿病大鼠睾丸生殖细胞的保护作用[J].中国老年学杂志,2011,31(13):2459-2461.
[10] 智二磊,徐计秀,王璟琦,等.血清抗精子抗体阳性对青春期雄性大鼠睾丸组织及睾丸生殖细胞中Fas/Fas-L凋亡途径的影响[J].中华男科学杂志,2013,19(2):111-115.
[11] Aramwit P, Siritientong T, Srichana T. Potential applications of silk sericin, a natural protein from textile industry by-products. Waste Manag Res. 2012;30(3):217-224.
[12] 彭乙华,曾恒礼,蔡燕,等.灯盏花素联合甲钴胺治疗糖尿病周围神经病变临床疗效分析[J].临床和实验医学杂志,2012,11(13): 1003-1005.
[13] 缪东军,邓丽萍,曾祥建,等.灯盏花素对链脲佐菌素诱导糖尿病大鼠的膀胱逼尿肌的影响[J].中国伤残医学,2013,1(4):56-57.
[14] 宋成军,付文亮,钟美蓉,等.丝胶对2型糖尿病大鼠睾丸c-fos表达的影响[J].中国老年学杂志,2011,31(20):3958-3960.
[15] 罗广承,何志华,罗建珍,等.构建糖尿病膀胱病豚鼠模型及其尿动力学评价[J].中国组织工程研究,2014,1(7):1063-1068.
[16] 杨汝斌,万屏,刘玲,等.灯盏花素灌胃对紫外线致SD大鼠皮肤光老化的保护作用[J].中国皮肤性病学杂志,2012,26(6):480-486.
[17] 苏哲君,孟凡利,付文亮,等.2型糖尿病大鼠睾丸PCNA表达的变化及丝胶的保护作用[J].中国老年学杂志,2012,32(1):88-90.
[18] 王翀,马小茹,宋明明,等.山楂总黄酮对糖尿病大鼠睾丸保护作用及其对PCNA表达的影响[J].牡丹江医学院学报,2014,35(4): 1-4.
[19] 廖波,邓显忠,曾德朗,等.糖尿病大鼠睾丸附睾形态及细胞数量的变化[J].山东医药,2012,52(34):18-21.
[20] 丁明建,丛晓东,张云,等.糖尿病并发男性性功能低下的机制及中药对其治疗作用[J].中国临床药理学杂志,2012,28(3):238-240.
[21] 徐志鹏,戴玉田.糖尿病与男性生殖内分泌[J].国际生殖健康/计划生育杂志,2014,33(6):455-459.
[22] 赵红斌,王剑锋,王旭,等.多氯联苯对大鼠骨髓间充质干细胞c-fos和c-jun表达影响的研究[J].卫生研究,2012,41(2):180-185.
[23] 王燕,史海涛,秦斌,等.Ghrelin对大鼠小肠转运的作用及对中枢和胃肠道c-fos表达的影响 [J].山东大学学报(医学版),2012, 35(11): 611-617.
[24] 堵安庆,王羽,赵森,等.周期性张应力作用下成骨样细胞MG-63中c-fos基因和丝状肌动蛋白相互关系的研究[J].华西口腔医学杂志, 2012,30(4):430-434.
[25] 史琨,张晓丽,张海玉,等.脂多糖所致小鼠睾丸支持细胞GDNF表达减少对精原干细胞的影响[J].山东大学学报(医学版),2013, 51(3):32-42.
[26] 安英,杨宁江,李强,等.灯盏花素预适应对大鼠肢体缺血再灌注肝损伤的保护作用[J].实用医学杂志,2013,29(4):543-545.
[27] 赵连志,苏玲,龚明玉,等.灯盏花素抑制缺氧/复氧大鼠心肌细胞JAK2的表达[J].中成药,2012,34(5):819-822.
[28] 肖云,肖洁,谢辉,等.灯盏花素联合还原型谷胱甘肽治疗糖尿病肾病的临床疗效[J].中国老年学杂志,2014,34(8):2042-2044.
[29] 马倩倩,李锦平,武莉,等.灯盏花素对2型糖尿病大鼠急性心肌缺血的保护作用[J].中药药理与临床,2014,30(2):72-76.
[30] 陈子洁,石理,陈曦,等.灯盏花素对对比剂急性肾损伤大鼠肾脏Na+,K+-ATP酶活性的影响[J].广东医学,2014,35(7):978-981.
[31] Ma Y, Li H, Guan S. Enhancement of the oral bioavailability of breviscapine by nanoemulsions drug delivery system. Drug Dev Ind Pharm. 2015;41(2):177-182.
[32] Zhou Y, Ning Q, Yu DN, et al. Improved oral bioavailability of breviscapine via a Pluronic P85-modified liposomal delivery system. J Pharm Pharmacol. 2014;66(7):903-911.
[33] Li M, Zheng Y, Shan FY, et al. Development of ionic-complex-based nanostructured lipid carriers to improve the pharmacokinetic profiles of breviscapine. Acta Pharmacol Sin. 2013;34(8):1108-1115.
[34] Wei L, Li G, Yan YD, et al. Lipid emulsion as a drug delivery system for breviscapine: formulation development and optimization. Arch Pharm Res. 2012;35(6):1037-1043.
[35] Liu Y, Li X, Yang C, et al. UPLC-MS-MS method for simultaneous determination of caffeine, tolbutamide, metoprolol, and dapsone in rat plasma and its application to cytochrome P450 activity study in rats. J Chromatogr Sci. 2013;51(1):26-32.
[36] He M, Xue ZM, Li J, et al. Breviscapine inhibits high glucose-induced proliferation and migration of cultured vascular smooth muscle cells of rats via suppressing the ERK1/2 MAPK signaling pathway. Acta Pharmacol Sin. 2012; 33(5):606-614.
[37] Gong YJ, Wang JX, Zhang Y, et al. Intestinal lymphatic transport of breviscapine orally administered in rat. Yao Xue Xue Bao. 2011;46(10):1262-1267.
[38] Wang M, Xie C, Cai RL, et al. Studies on antioxidant activities of breviscapine in the cell-free system. Am J Chin Med. 2008; 36(6):1199-207.
[39] Liu M, Li H, Luo G, et al. Pharmacokinetics and biodistribution of surface modification polymeric nanoparticles. Arch Pharm Res. 2008;31(4):547-554.
[40] Zhong H, Deng Y, Wang X, et al. Multivesicular liposome formulation for the sustained delivery of breviscapine. Int J Pharm. 2005;301(1-2):15-24